← SynDRA
DAPAGLIFLOZIN
SynDRA canonical compound SYN0009292 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | SLC5A1 | SLC5A2 |
|---|
| Mechanism of action | sodium/glucose cotransporter inhibitor |
|---|
| Indication | diabetes mellitus |
|---|
| Disease area | endocrinology |
|---|
All known targets
- SLC5A2
- SLC5A1
- SLC5A11
- SLC5A4
- Slc5a2
Mechanisms of action (all sources)
- SLC5A2 INHIBITOR
- Sodium/glucose cotransporter 2 inhibitor
- sodium/glucose cotransporter inhibitor
- SLC5A2 MODULATOR
Drug classes
- Hypoglycemic Agents
- Sodium-Glucose Transporter 2 Inhibitors
- Sodium-Glucose Cotransporter 2 Inhibitor
ATC classes
- A10B · BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Cross-references
Synonyms
- dapagliflozin propanediol monohydrate
- dapagliflozin propanediol
- BMS 512148
- forxiga
- dapaglifozin
- farxiga
- dapagliflozin propylene glycolate hydrate
- Dapagliflozine
- Dapagliflozina
- BMS-512148
- LYN-045
- Dapagliflozin component of br1019
- Dapagliflozin component of qtern
- Dapagliflozin component of qternmet
- Dapagliflozin component of qternmet dapaglifozin
- Dapagliflozin component of qternmet xr
- Dapagliflozin viatris
- BMS-512148, Dapagliflozin
- Dapagliflozin (INN/USAN)
- 2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
- DAPAGLIFLOZIN COMPONENT QTERNMET
- 1ULL0QJ8UC
- BR1019 component Dapagliflozin
- QTERNMET XR COMPONENT DAPAGLIFLOZIN
- QTERNMET COMPONENT DAPAGLIFOZIN
- dapagliflozine
- CHEBI:85078
- BMS512148
- dapagliflozinum
- RefChem:54930
- A10BK01
- DTXCID101334207
- Dagagflozin
- MFCD13182359
- Dapagliflozin [USAN:INN]
- Forxiga (TN)
- Dapagliflozin [USAN]
- C21H25ClO6
Reported adverse events
- Rash
- Urinary tract infection
- Escherichia urinary tract infection
- Constipation
- Back pain
- Infection
- Hypersensitivity
- Ketoacidosis
- Pyelonephritis
- Urosepsis
- Influenza
- Nasopharyngitis
Look up DAPAGLIFLOZIN in the interactive SynDRA portal →